An Update on COVID-19 Vaccine Induced Thrombotic Thrombocytopenia Syndrome and Some Management Recommendations

• Published in: Molecules (Basel, Switzerland) Vol. 26; no. 16; p. 5004
• Main Authors: Islam, Amin, Bashir, Mohammed Sheraz, Joyce, Kevin, Rashid, Harunor, Laher, Ismail, Elshazly, Shereen
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.08.2021; MDPI
• Subjects: Adenoviruses; Antibodies - blood; Anticoagulants; Asymptomatic; Coronaviruses; COVID-19; COVID-19 vaccine; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Cytokines; Diagnosis, Differential; disseminated intravascular coagulation; Embolism; Fibrinogen; Fibrinolysis; Health risks; Heparin; Heparin - adverse effects; heparin induced thrombocytopenia; Humans; Infections; Ischemia; Pathophysiology; Patients; Platelet factor 4; Platelet Factor 4 - blood; Review; Risk analysis; Risk factors; Severe acute respiratory syndrome coronavirus 2; Surfactants; Thrombocytopenia; Thrombocytopenia - chemically induced; Thrombocytopenia - etiology; Thrombocytopenia - therapy; Thromboembolism; Thrombosis; Thrombosis - chemically induced; Thrombosis - etiology; Thrombosis - therapy; Vaccines; Viral infections; Viruses; Beijing China; Scotland; United Kingdom > UK; United States > US; China; Russia; COVID-19; vaccine induced thrombocytopenia and thrombosis; thrombosis; platelet factor 4; heparin induced thrombocytopenia; COVID-19 vaccine; thrombotic thrombo-cytopenic purpura; disseminated intravascular coagulation

The thrombotic thrombocytopenia syndrome (TTS), a complication of COVID-19 vaccines, involves thrombosis (often cerebral venous sinus thrombosis) and thrombocytopenia with occasional pulmonary embolism and arterial ischemia. TTS appears to mostly affect females aged between 20 and 50 years old, with...